• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pathobiology: journal of immunopathology, molecular and cellular biology >Future perspectives for the development of chemotherapy for advanced gastric cancer: Japanese and global status
【24h】

Future perspectives for the development of chemotherapy for advanced gastric cancer: Japanese and global status

机译：晚期胃癌化学疗法发展的未来前景：日本和全球地位

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In Japan, gastric cancer is the second leading cause of cancer-related mortality after lung cancer. Many randomized trials of various chemotherapeutic regimens have been conducted, contributing to improved outcomes in patients with advanced gastric cancer (AGC). The standard regimen for AGC is a combination of S-1 and cisplatin in Japan. Recently, new drug development has focused on molecular target agents, and personalized therapy for AGC has just begun. In patients with human epidermal growth factor receptor 2-positive AGC, trastuzumab in combination with chemotherapy improves survival. Furthermore, abundant information about the heterogeneity and biological backgrounds of AGC patients has been compiled. New strategies for the development of personalized therapy should be studied in the future.
机译：在日本，胃癌是仅次于肺癌的第二大癌症相关死亡原因。已经进行了多种化疗方案的许多随机试验，有助于改善晚期胃癌（AGC）患者的预后。在日本，AGC的标准方案是S-1和顺铂的组合。最近，新药的开发集中在分子靶向药物上，而针对AGC的个性化治疗才刚刚开始。在具有人类表皮生长因子受体2阳性AGC的患者中，曲妥珠单抗联合化疗可提高生存率。此外，关于AGC患者异质性和生物学背景的大量信息已被汇编。未来应研究开发个性化疗法的新策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号